<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064462</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201167</org_study_id>
    <secondary_id>2020-A03456-33</secondary_id>
    <nct_id>NCT05064462</nct_id>
  </id_info>
  <brief_title>TTV Viral Load in Heart Transplant Recipients</brief_title>
  <acronym>TTVCoeur</acronym>
  <official_title>Association Between TTV Viral Load and the Occurrence of Infections and Rejection in Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicenter, non-interventional trial aims to study the association between&#xD;
      TTV viral load and the occurrence of rejection or infection during the first year after&#xD;
      transplantation.&#xD;
&#xD;
      The TTV viral loads, taken once a month during the first year after the transplant, will be&#xD;
      measured at the end of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TTV (Torque Teno Virus) is a ubiquitous virus that is not associated with any disease. A&#xD;
      correlation exists between the level of TTV replication and the subject's immunocompetence:&#xD;
      weak or non-existent in immunocompetents, very high in immunocompromised patients. In heart&#xD;
      transplant patients, pharmacological dosing of immunosuppressants prevents their toxic&#xD;
      manifestations but is not correlated with individual immune competence. Only clinical&#xD;
      manifestations of overdose (infections) or under dosage (rejections) currently allow&#xD;
      optimization of immunosuppressants. A predictive biomarker of these clinical manifestations&#xD;
      upstream of their appearance would revolutionize the management of these patients.&#xD;
&#xD;
      The TTV fulfills the conditions to be an ideal biomarker: classic blood sampling, possible&#xD;
      follow-up in all patients, low cost, carrying out the analysis on already existing molecular&#xD;
      biology platforms, reproducibility of inter- and intra-laboratory results, defined thresholds&#xD;
      for the reliable interpretation of the results.&#xD;
&#xD;
      We believe that this marker will provide the clinician with a useful tool for the management&#xD;
      of immunosuppressants and the patient with personalized medicine which will allow their&#xD;
      management to be individualized. If this study confirms the expected results, then it will&#xD;
      allow, secondly, the setting up of interventional studies to validate the TTV viral load as a&#xD;
      biomarker, and a tool for piloting immunosuppressive treatment.&#xD;
&#xD;
      The TTV viral load of heart transplant patients will be follow during the first year after&#xD;
      transplantation.&#xD;
&#xD;
      A tube of blood will be taken during the transplant and then once or twice a month.&#xD;
&#xD;
      Samples will be taken at the same time as those taken as part of standard care. The TTV viral&#xD;
      load will be measured at the end of the study.&#xD;
&#xD;
      The occurrence of events of interest (infections and rejections) will be collected at each&#xD;
      corresponding visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome : Infections or Rejections</measure>
    <time_frame>12 months</time_frame>
    <description>All infections during the 12 months post-transplant including :&#xD;
Viral Infections , bacterial and parasitic infections requiring the establishment of anti-infectious treatment or hospitalization.&#xD;
All rejections during the 12 months post-transplant including :&#xD;
Acute type 2R or 3R cell rejections according to the ISHLT classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTV viral load</measure>
    <time_frame>3 months</time_frame>
    <description>TTV viral load measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTV viral load</measure>
    <time_frame>12 months</time_frame>
    <description>TTV viral load measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months</time_frame>
    <description>All infections during the 12 months post-transplant including :&#xD;
Viral Infections , bacterial and parasitic infections requiring the establishment of anti-infectious treatment or hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rejections</measure>
    <time_frame>12 months</time_frame>
    <description>All rejections during the 12 months post-transplant including :&#xD;
Acute type 2R or 3R cell rejections according to the ISHLT classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunosuppressant level</measure>
    <time_frame>3 months</time_frame>
    <description>Immunosuppressant pharmacological dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunosuppressant level</measure>
    <time_frame>12 months</time_frame>
    <description>Immunosuppressant pharmacological dosing</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Transplant Rejection</condition>
  <condition>Heart Transplant Infection</condition>
  <condition>Virus</condition>
  <arm_group>
    <arm_group_label>All the patients included in the study</arm_group_label>
    <description>50 patients, at least 18 years old, first heart transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of EDTA blood sample (5 to 7 ml)</intervention_name>
    <description>For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).&#xD;
These samples will be taken at the same time as those taken as part of standard care.</description>
    <arm_group_label>All the patients included in the study</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5-7 ml whole blood samples are taken at each monthly visit to measure viral load at the end&#xD;
      of the study.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with first heart transplant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Heart transplant only&#xD;
&#xD;
          -  First transplant&#xD;
&#xD;
          -  Patient not having objected to carrying out the research&#xD;
&#xD;
          -  Affiliated to a French Health Insurance system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient transplanted from more than one solid organ&#xD;
&#xD;
          -  Patient who has already been transplanted before&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène PERE, Pharm D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David VEYER, Pharm D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ophélie ROGIER, MSc</last_name>
    <phone>+33 (0)1 44 84 17 89</phone>
    <email>ophelie.rogier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malha BERRAH, MSc</last_name>
    <phone>+33 (0)1 56 09 58 22</phone>
    <email>malha.berrah@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain GUILLEMAIN, MD</last_name>
      <phone>+33 (0)1 56 09 29 64</phone>
      <email>guillemain.hegp@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bernard LELONG, MD</last_name>
      <phone>+33 (0)2 99 28 91 84</phone>
      <email>bernard.lelong@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Jacques VON HUNOLSTEIN, MD</last_name>
      <phone>+33 (0)3 95 55 09 43</phone>
      <email>vonhunolstein@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TTV, Heart transplant, Viral Load, rejection, infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Two years after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and IP team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

